Pure Global
NCT06104644

A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany (DELPHIN)

Deucravacitinib in Routine Clinical Practice: A 5-year, Multicenter, Prospective, Non-Interventional Cohort Study to Evaluate Effectiveness and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis in Germany (DELPHIN)
Bristol-Myers Squibb·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Plaque Psoriasis
Drug/Device/Intervention
Deucravacitinib
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Bristol-Myers Squibb
Location
Selters, Germany
Timeline & enrollment
Phase
N/A
Start date
Apr 13, 2023
End date
Apr 30, 2030
Enrollment
450 participants
Primary outcome

Proportion of patients achieving an absolute Psoriasis Area Severity Index (aPASI) score ≤ 3 at Week 24 or nearest visit

Summary

The purpose of this observational study is to describe the effectiveness of deucravacitinib
 treatment and quality of life in adults with moderate-to-severe plaque psoriasis in routine
 clinical practice in Germany over a 5-year period

ICD-10 classifications
PsoriasisLarge plaque parapsoriasisOther psoriasisSmall plaque parapsoriasisArthropathic psoriasis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06104644
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06104644 through Pure Global AI's free database. This phase not specified trial is sponsored by Bristol-Myers Squibb and is currently Recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 450 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.